{"type":"Disease","attribute_content":[],"id":"10528","alternate_symbols":[],"xrefs":[],"alternate_names":[],"keywords":[],"medgen_id":"C2673535","name":"Dystonia, dopa-responsive, with or without hyperphenylalaninemia, autosomal recessive"}
{"type":"Disease","attribute_content":[],"id":"6364","alternate_symbols":[],"xrefs":["{\"db\":\"Genetic Alliance\",\"id\":\"Caroli+Disease/1117\",\"ref_field\":\"name\"}"],"alternate_names":["Caroli disease isolated","Congenital polycystic dilatation of intrahepatic bile ducts","Cystic dilatation of the intrahepatic biliary tree"],"keywords":[],"medgen_id":"C0162510","name":"Caroli disease"}
{"type":"Disease","attribute_content":[],"id":"9156","public_definition":"Caudal regression syndrome is a disorder that impairs the development of the lower (caudal) half of the body. Affected areas can include the lower back and limbs, the genitourinary tract, and the gastrointestinal tract.In this disorder, the bones of the lower spine (vertebrae) are frequently misshapen or missing, and the corresponding sections of the spinal cord are also irregular or missing. Affected individuals may have incomplete closure of the vertebrae around the spinal cord, a fluid-filled sac on the back covered by skin that may or may not contain part of the spinal cord, or tufts of hair at the base of the spine. People with caudal regression syndrome can also have an abnormal side-to-side curvature of the spine (scoliosis). The spinal abnormalities may affect the size and shape of the chest, leading to breathing problems in some individuals.Individuals with caudal regression syndrome may have small hip bones with a limited range of motion. The buttocks tend to be flat and dimpled. The bones of the legs are typically underdeveloped, most frequently the upper leg bones (femurs). In some individuals, the legs are bent with the knees pointing out to the side and the feet tucked underneath the hips (sometimes called a frog leg-like position). Affected individuals may be born with inward- and upward-turning feet (clubfeet), or the feet may be outward- and upward-turning (calcaneovalgus). Some people experience decreased sensation in their lower limbs.Abnormalities in the genitourinary tract in caudal regression syndrome are extremely varied. Often the kidneys are malformed; defects include a missing kidney (unilateral renal agenesis), kidneys that are fused together (horseshoe kidney), or duplication of the tubes that carry urine from each kidney to the bladder (ureteral duplication). These kidney abnormalities can lead to frequent urinary tract infections and progressive kidney failure. Additionally, affected individuals may have protrusion of the bladder through an opening in the abdominal wall (bladder exstrophy). Damage to the nerves that control bladder function, a condition called neurogenic bladder, causes affected individuals to have progressive difficulty controlling the flow of urine. Genital abnormalities in males can include the urethra opening on the underside of the penis (hypospadia) or undescended testes (cryptorchidism). Females may have an abnormal connection between the rectum and vagina (rectovaginal fistula). In severe cases, both males and females have a lack of development of the genitalia (genital agenesis).People with caudal regression syndrome may have abnormal twisting (malrotation) of the large intestine, an obstruction of the anal opening (imperforate anus), soft out-pouchings in the lower abdomen (inguinal hernias), or other malformations of the gastrointestinal tract. Affected individuals are often constipated and may experience loss of control of bladder and bowel function.","alternate_symbols":[],"xrefs":["{\"db\":\"Genetic Alliance\",\"id\":\"Caudal+Regression+Syndrome/1174\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"caudal-regression-syndrome\",\"ref_field\":\"public_definition\"}"],"alternate_names":["Caudal dysplasia"],"keywords":[],"medgen_id":"C0300948","name":"Caudal regression syndrome"}
{"type":"Disease","attribute_content":[],"id":"5604","public_definition":"Idiopathic inflammatory myopathy is a group of disorders characterized by inflammation of the muscles used for movement (skeletal muscles). Idiopathic inflammatory myopathy usually appears in adults between ages 40 and 60 or in children between ages 5 and 15, though it can occur at any age.The primary symptom of idiopathic inflammatory myopathy is muscle weakness, which develops gradually over a period of weeks to months or even years. Other symptoms include joint pain and general tiredness (fatigue).There are several forms of idiopathic inflammatory myopathy, including polymyositis, dermatomyositis, and sporadic inclusion body myositis.Polymyositis and dermatomyositis involve weakness of the muscles closest to the center of the body (proximal muscles), such as the muscles of the hips and thighs, upper arms, and neck. People with these forms of idiopathic inflammatory myopathy may find it difficult to climb stairs, get up from a seated position, or lift items above their head. In some cases, muscle weakness may make swallowing or breathing difficult.Polymyositis and dermatomyositis have similar symptoms, but dermatomyositis is distinguished by a reddish or purplish rash on the eyelids, elbows, knees, or knuckles. Sometimes, abnormal calcium deposits form hard, painful bumps under the skin (calcinosis).In sporadic inclusion body myositis, the muscles most affected are those of the wrists and fingers and the front of the thigh. Affected individuals may frequently stumble while walking and find it difficult to grasp items. As in dermatomyositis and polymyositis, swallowing can be difficult.","alternate_symbols":[],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100614\",\"type\":\"primary\"}","{\"db\":\"OMIM\",\"id\":\"160750\",\"type\":\"MIM\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Idiopathic+myopathy/3755\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Idiopathic myopathy\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100614\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"idiopathic-inflammatory-myopathy\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"160750\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":["Idiopathic inflammatory myopathy","Idiopathic inflammatory myopathy, familial","Idiopathic myopathy"],"keywords":[],"medgen_id":"C0027121","symbol":"IIM","name":"Myositis"}
{"type":"Disease","attribute_content":[],"id":"9864","alternate_symbols":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0013160\"}","{\"db\":\"OMIM\",\"id\":\"613156\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"613156\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY, CONGENITAL, POMT2-RELATED\"}","{\"db\":\"OMIM\",\"id\":\"607439.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH IMPAIRED INTELLECTUAL DEVELOPMENT), TYPE B, 2\"}","{\"db\":\"OMIM\",\"id\":\"607439.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH IMPAIRED INTELLECTUAL DEVELOPMENT), TYPE B, 2\"}","{\"db\":\"OMIM\",\"id\":\"607439.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH IMPAIRED INTELLECTUAL DEVELOPMENT), TYPE B, 2\"}","{\"db\":\"OMIM\",\"id\":\"607439.0014\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH IMPAIRED INTELLECTUAL DEVELOPMENT), TYPE B, 2\"}","{\"db\":\"OMIM\",\"id\":\"607439.0015\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH IMPAIRED INTELLECTUAL DEVELOPMENT), TYPE B, 2\"}","{\"db\":\"OMIM\",\"id\":\"607439.0016\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH IMPAIRED INTELLECTUAL DEVELOPMENT), TYPE B, 2\"}","{\"db\":\"OMIM\",\"id\":\"607439.0017\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH IMPAIRED INTELLECTUAL DEVELOPMENT), TYPE B, 2\"}","{\"db\":\"OMIM\",\"id\":\"613156\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH IMPAIRED INTELLECTUAL DEVELOPMENT), TYPE B, 2\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Congenital+muscular+dystrophy-dystroglycanopathy+with+mental+retardation%2C+type+B2/8073\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"613156\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":["MUSCULAR DYSTROPHY, CONGENITAL, POMT2-RELATED","MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH IMPAIRED INTELLECTUAL DEVELOPMENT), TYPE B, 2"],"keywords":[],"medgen_id":"C3150416","symbol":"MDDGB2","name":"Congenital muscular dystrophy-dystroglycanopathy with mental retardation, type B2"}
{"type":"Disease","attribute_content":[],"id":"9867","alternate_symbols":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0013159\"}","{\"db\":\"OMIM\",\"id\":\"613155\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"613155\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY, CONGENITAL, POMT1-RELATED\"}","{\"db\":\"OMIM\",\"id\":\"613155\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH IMPAIRED INTELLECTUAL IMPAIRMENT), TYPE B, 1\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Congenital+muscular+dystrophy-dystroglycanopathy+with+mental+retardation%2C+type+B1/8072\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"613155\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":["MUSCULAR DYSTROPHY, CONGENITAL, POMT1-RELATED","MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH IMPAIRED INTELLECTUAL IMPAIRMENT), TYPE B, 1"],"keywords":[],"medgen_id":"C3150415","symbol":"MDDGB1","name":"Congenital muscular dystrophy-dystroglycanopathy with mental retardation, type B1"}
{"type":"Disease","attribute_content":[],"id":"1740","alternate_symbols":["FPH2","MUH"],"xrefs":["{\"db\":\"OMIM\",\"id\":\"145250\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"280628\"}","{\"db\":\"Orphanet\",\"id\":\"79146\"}","{\"db\":\"Orphanet\",\"id\":\"79146\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Familial progressive hyperpigmentation\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Hyperpigmentation%2C+familial+progressive%2C+2/8601\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Hyperpigmentation, familial progressive, 2\"}","{\"db\":\"OMIM\",\"id\":\"145250\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MELANOSIS UNIVERSALIS HEREDITARIA\"}","{\"db\":\"OMIM\",\"id\":\"145250\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"FPH2\"}","{\"db\":\"OMIM\",\"id\":\"145250\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"MUH\"}","{\"db\":\"OMIM\",\"id\":\"145250\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":["Congenital hypomelanotic and hypermelanotic macules","Familial progressive hyperpigmentation","Hyperpigmentation, familial progressive, 2","MELANOSIS UNIVERSALIS HEREDITARIA"],"keywords":[],"medgen_id":"C1840392","symbol":"FPHH","name":"Familial progressive hyperpigmentation with or without hypopigmentation"}
{"type":"Disease","attribute_content":[],"id":"35561","alternate_symbols":[],"xrefs":["{\"db\":\"MeSH\",\"id\":\"D010190\"}"],"alternate_names":[],"keywords":[],"medgen_id":"C0030297","name":"Pancreatic Neoplasms"}
{"type":"Disease","attribute_content":[],"id":"18197","alternate_symbols":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0014141\"}","{\"db\":\"OMIM\",\"id\":\"615351\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"615351\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY, CONGENITAL, GMPPB-RELATED\"}","{\"db\":\"OMIM\",\"id\":\"615320.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH IMPAIRED INTELLECTUAL DEVELOPMENT), TYPE B, 14\"}","{\"db\":\"OMIM\",\"id\":\"615320.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH IMPAIRED INTELLECTUAL DEVELOPMENT), TYPE B, 14\"}","{\"db\":\"OMIM\",\"id\":\"615320.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH IMPAIRED INTELLECTUAL DEVELOPMENT), TYPE B, 14\"}","{\"db\":\"OMIM\",\"id\":\"615351\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH IMPAIRED INTELLECTUAL DEVELOPMENT), TYPE B, 14\"}","{\"db\":\"OMIM\",\"id\":\"615351\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":["Congenital muscular dystrophy-dystroglycanopathy with mental retardation, type B14","MUSCULAR DYSTROPHY, CONGENITAL, GMPPB-RELATED","MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH IMPAIRED INTELLECTUAL DEVELOPMENT), TYPE B, 14"],"keywords":[],"medgen_id":"C3809221","symbol":"MDDGB14","name":"Muscular dystrophy-dystroglycanopathy (congenital with mental retardation), type b, 14"}
{"type":"Disease","attribute_content":[],"id":"1406","alternate_symbols":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0009510\"}","{\"db\":\"OMIM\",\"id\":\"245590\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"220465\"}","{\"db\":\"OMIM\",\"id\":\"245590\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GROWTH HORMONE INSENSITIVITY SYNDROME WITH IMMUNE DYSREGULATION 1, AUTOSOMAL RECESSIVE\"}","{\"db\":\"OMIM\",\"id\":\"604260.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GROWTH HORMONE INSENSITIVITY SYNDROME WITH IMMUNE DYSREGULATION 1, AUTOSOMAL RECESSIVE\"}","{\"db\":\"OMIM\",\"id\":\"604260.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GROWTH HORMONE INSENSITIVITY SYNDROME WITH IMMUNE DYSREGULATION 1, AUTOSOMAL RECESSIVE\"}","{\"db\":\"OMIM\",\"id\":\"604260.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GROWTH HORMONE INSENSITIVITY SYNDROME WITH IMMUNE DYSREGULATION 1, AUTOSOMAL RECESSIVE\"}","{\"db\":\"OMIM\",\"id\":\"604260.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GROWTH HORMONE INSENSITIVITY SYNDROME WITH IMMUNE DYSREGULATION 1, AUTOSOMAL RECESSIVE\"}","{\"db\":\"OMIM\",\"id\":\"604260.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GROWTH HORMONE INSENSITIVITY SYNDROME WITH IMMUNE DYSREGULATION 1, AUTOSOMAL RECESSIVE\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Growth+Hormone+Insensitivity+with+Immunodeficiency/3194\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Growth hormone insensitivity with immunodeficiency\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0009510\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"245590\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":["GROWTH HORMONE INSENSITIVITY SYNDROME WITH IMMUNE DYSREGULATION 1, AUTOSOMAL RECESSIVE","Growth hormone insensitivity due to postreceptor defect","Growth hormone insensitivity with immunodeficiency","Laron syndrome due to postreceptor defect"],"keywords":[],"medgen_id":"C1855548","symbol":"GHISID1","name":"Laron syndrome with immunodeficiency"}
{"type":"Disease","attribute_content":[],"id":"228","alternate_symbols":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0011469\"}","{\"db\":\"OMIM\",\"id\":\"604498\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"3319\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Congenital+Amegakaryocytic+Thrombocytopenia/1779\",\"ref_field\":\"name\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0011469\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"604498\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":[],"keywords":[],"medgen_id":"C1327915","symbol":"CAMT","name":"Congenital amegakaryocytic thrombocytopenia"}
{"type":"Disease","attribute_content":[],"id":"40645","alternate_symbols":[],"xrefs":[],"alternate_names":[],"keywords":[],"medgen_id":"C0752304","name":"Hypoxic Ischemic Encephalopathy"}
{"type":"Disease","attribute_content":[],"id":"36343","alternate_symbols":[],"xrefs":["{\"db\":\"OMIM\",\"id\":\"617207\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"617207\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":[],"keywords":[],"medgen_id":"C4310667","symbol":"PEAMO","name":"Encephalopathy, progressive, with amyotrophy and optic atrophy"}
{"type":"Disease","attribute_content":[],"id":"6277","alternate_symbols":[],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0011901\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0011901\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Dysfibrinogenaemia\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Dysfibrinogenemia/2380\",\"ref_field\":\"name\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0011901\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"111589005\",\"ref_field\":\"name\"}"],"alternate_names":["Congenital dysfibrinogenemia","Dysfibrinogenaemia","Dysfibrinogenemia, familial"],"keywords":[],"medgen_id":"C1260903","name":"Dysfibrinogenemia"}
{"type":"Disease","attribute_content":[],"id":"6937","gard_id":"10522","alternate_symbols":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0013116\"}","{\"db\":\"OMIM\",\"id\":\"613076\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"330054\"}","{\"db\":\"OMIM\",\"id\":\"613076\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MITOCHONDRIAL COMPLEX DEFICIENCY, COMBINED\"}","{\"db\":\"OMIM\",\"id\":\"613076\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MYOPATHY WITH CATARACT AND COMBINED RESPIRATORY CHAIN DEFICIENCY\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10522\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Myopathy%2C+mitochondrial+progressive%2C+with+congenital+cataract%2C+hearing+loss%2C+and+developmental+delay/8957\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"613076\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":["MITOCHONDRIAL COMPLEX DEFICIENCY, COMBINED","MYOPATHY WITH CATARACT AND COMBINED RESPIRATORY CHAIN DEFICIENCY"],"keywords":[],"medgen_id":"C2751320","symbol":"MPMCD","name":"Myopathy, mitochondrial progressive, with congenital cataract, hearing loss, and developmental delay"}
{"type":"Disease","attribute_content":[],"id":"16776","gard_id":"12724","alternate_symbols":[],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0032388\",\"type\":\"primary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0020341\"}","{\"db\":\"MeSH\",\"id\":\"D054091\"}","{\"db\":\"OMIM\",\"id\":\"PS300049\",\"type\":\"Phenotypic series\"}","{\"db\":\"Orphanet\",\"id\":\"98892\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"12724\",\"ref_field\":\"gard_id\"}","{\"db\":\"OMIM\",\"id\":\"PS300049\",\"type\":\"Phenotypic series\",\"ref_field\":\"name\"}"],"alternate_names":[],"keywords":[],"medgen_id":"C1868720","symbol":"PVNH","name":"Periventricular nodular heterotopia"}
{"type":"Disease","attribute_content":[],"id":"29631","alternate_symbols":[],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0011736\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0011736\",\"ref_field\":\"name\"}"],"alternate_names":["Conn's syndrome"],"keywords":[],"medgen_id":"C1384514","name":"Primary hyperaldosteronism"}
{"type":"Disease","attribute_content":[],"id":"10032","alternate_symbols":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0013155\"}","{\"db\":\"OMIM\",\"id\":\"613151\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"613151\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY, CONGENITAL, POMGNT1-RELATED\"}","{\"db\":\"OMIM\",\"id\":\"606822.0014\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH IMPAIRED INTELLECTUAL DEVELOPMENT), TYPE B, 3\"}","{\"db\":\"OMIM\",\"id\":\"606822.0015\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH IMPAIRED INTELLECTUAL DEVELOPMENT), TYPE B, 3\"}","{\"db\":\"OMIM\",\"id\":\"606822.0016\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH IMPAIRED INTELLECTUAL DEVELOPMENT), TYPE B, 3\"}","{\"db\":\"OMIM\",\"id\":\"613151\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH IMPAIRED INTELLECTUAL DEVELOPMENT), TYPE B, 3\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Congenital+muscular+dystrophy-dystroglycanopathy+with+mental+retardation%2C+type+B3/8074\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"613151\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":["MUSCULAR DYSTROPHY, CONGENITAL, POMGNT1-RELATED","MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH IMPAIRED INTELLECTUAL DEVELOPMENT), TYPE B, 3"],"keywords":[],"medgen_id":"C3150412","symbol":"MDDGB3","name":"Congenital muscular dystrophy-dystroglycanopathy with mental retardation, type B3"}
{"type":"Disease","attribute_content":[],"id":"4769","content":"{\"Citation\":{\"@Abbrev\":\"EFNS, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"20298421\",\"@Source\":\"PubMed\"}}}","alternate_symbols":["HCHWAD"],"xrefs":["{\"db\":\"OMIM\",\"id\":\"605714\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"100006\"}","{\"db\":\"Orphanet\",\"id\":\"324703\"}","{\"db\":\"Orphanet\",\"id\":\"324708\"}","{\"db\":\"Orphanet\",\"id\":\"324713\"}","{\"db\":\"Orphanet\",\"id\":\"324718\"}","{\"db\":\"Orphanet\",\"id\":\"324723\"}","{\"db\":\"Orphanet\",\"id\":\"85458\"}","{\"db\":\"OMIM\",\"id\":\"605714\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"AMYLOIDOSIS, CEREBROARTERIAL, APP-RELATED\"}","{\"db\":\"OMIM\",\"id\":\"605714\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"HCHWAD\"}"],"alternate_names":["AMYLOIDOSIS, CEREBROARTERIAL, APP-RELATED"],"keywords":[],"medgen_id":"C2751536","name":"Cerebral amyloid angiopathy, APP-related"}
{"type":"Disease","attribute_content":[],"id":"6847","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301468\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1291\",\"@Source\":\"BookShelf\"}]}}","alternate_symbols":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0013156\"}","{\"db\":\"OMIM\",\"id\":\"613152\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"613152\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY, CONGENITAL, FKTN-RELATED\"}","{\"db\":\"OMIM\",\"id\":\"607440.0009\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITHOUT IMPAIRED INTELLECTUAL DEVELOPMENT), TYPE B, 4\"}","{\"db\":\"OMIM\",\"id\":\"607440.0019\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITHOUT IMPAIRED INTELLECTUAL DEVELOPMENT), TYPE B, 4\"}","{\"db\":\"OMIM\",\"id\":\"613152\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITHOUT IMPAIRED INTELLECTUAL DEVELOPMENT), TYPE B, 4\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Congenital+muscular+dystrophy-dystroglycanopathy+without+mental+retardation%2C+type+B4/8076\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"613152\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":["MUSCULAR DYSTROPHY, CONGENITAL, FKTN-RELATED","MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITHOUT IMPAIRED INTELLECTUAL DEVELOPMENT), TYPE B, 4"],"keywords":[],"medgen_id":"C2751052","symbol":"MDDGB4","name":"Congenital muscular dystrophy-dystroglycanopathy without mental retardation, type B4"}
{"type":"Disease","attribute_content":[],"id":"246","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301496\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1321\",\"@Source\":\"BookShelf\"}]}}","gard_id":"668","alternate_symbols":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0010524\"}","{\"db\":\"OMIM\",\"id\":\"301310\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"2802\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Anemia+Sideroblastic+and+Spinocerebellar+Ataxia/444\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Anemia sideroblastic and spinocerebellar ataxia\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1321\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"X-Linked Sideroblastic Anemia and Ataxia\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"668\",\"ref_field\":\"gard_id\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0010524\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"301310\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":["Anemia sideroblastic and spinocerebellar ataxia","Pagon Bird Detter syndrome","Sideroblastic anemia with spinocerebellar ataxia","X-Linked Sideroblastic Anemia and Ataxia"],"keywords":[],"medgen_id":"C1845028","symbol":"ASAT","name":"X-linked sideroblastic anemia with ataxia"}
{"type":"Disease","attribute_content":[],"id":"993","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301598\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1425\",\"@Source\":\"BookShelf\"}]}}","public_definition":"C3 glomerulopathy (C3G) is a complex ultra-rare complement-mediated renal disease caused by uncontrolled activation of the complement alternative pathway (AP) in the fluid phase (as opposed to cell surface) that is rarely inherited in a simple mendelian fashion. C3G affects individuals of all ages, with a median age at diagnosis of 23 years. Individuals with C3G typically present with hematuria, proteinuria, hematuria and proteinuria, acute nephritic syndrome or nephrotic syndrome, and low levels of the complement component C3. Spontaneous remission of C3G is uncommon, and about half of affected individuals develop end-stage renal disease (ESRD) within ten years of diagnosis, occasionally developing the late comorbidity of impaired visual acuity.","alternate_symbols":[],"xrefs":["{\"db\":\"OMIM\",\"id\":\"609814\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"609814\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CFH DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"134370.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"COMPLEMENT FACTOR H DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"134370.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"COMPLEMENT FACTOR H DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"134370.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"COMPLEMENT FACTOR H DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"134370.0010\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"COMPLEMENT FACTOR H DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"134370.0013\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"COMPLEMENT FACTOR H DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"134370.0014\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"COMPLEMENT FACTOR H DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"134370.0017\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"COMPLEMENT FACTOR H DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"609814\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"COMPLEMENT FACTOR H DEFICIENCY\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Factor+H+deficiency/8366\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"234622003\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1425\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"609814\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":["CFH DEFICIENCY","COMPLEMENT FACTOR H DEFICIENCY"],"keywords":[],"medgen_id":"C0398777","symbol":"CFHD","name":"Factor H deficiency"}
{"type":"Disease","attribute_content":[],"id":"4035","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"23236640\",\"@Source\":\"PubMed\"},{\"$\":\"NBK114806\",\"@Source\":\"BookShelf\"}]}}","public_definition":"KAT6B disorders include genitopatellar syndrome (GPS) and Say-Barber-Biesecker-Young-Simpson variant of Ohdo syndrome (SBBYSS) which are part of a broad phenotypic spectrum with variable expressivity; individuals presenting with a phenotype intermediate between GPS and SBBYSS have been reported. Both phenotypes are characterized by some degree of global developmental delay / intellectual disability; hypotonia; genital abnormalities; and skeletal abnormalities including patellar hypoplasia/agenesis, flexion contractures of the knees and/or hips, and anomalies of the digits, spine, and/or ribs. Congenital heart defects, small bowel malrotation, feeding difficulties, slow growth, cleft palate, hearing loss, and dental anomalies have been observed in individuals with either phenotype.","alternate_symbols":["SBBYSS","YSS"],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0011365\"}","{\"db\":\"OMIM\",\"id\":\"603736\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"3047\"}","{\"db\":\"OMIM\",\"id\":\"603736\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OHDO SYNDROME, SBBYS VARIANT\"}","{\"db\":\"OMIM\",\"id\":\"603736\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SAY-BARBER-BIESECKER-YOUNG-SIMPSON SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"605880.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SAY-BARBER-BIESECKER-YOUNG-SIMPSON SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"605880.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SAY-BARBER-BIESECKER-YOUNG-SIMPSON SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"605880.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SAY-BARBER-BIESECKER-YOUNG-SIMPSON SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"605880.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SAY-BARBER-BIESECKER-YOUNG-SIMPSON SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"605880.0011\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SAY-BARBER-BIESECKER-YOUNG-SIMPSON SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"605880.0012\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SAY-BARBER-BIESECKER-YOUNG-SIMPSON SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"605880.0013\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SAY-BARBER-BIESECKER-YOUNG-SIMPSON SYNDROME\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Young+Simpson+syndrome/7589\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Young Simpson syndrome\"}","{\"db\":\"OMIM\",\"id\":\"603736\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"SBBYSS\"}","{\"db\":\"OMIM\",\"id\":\"603736\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"YSS\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0011365\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK114806\",\"ref_field\":\"public_definition\"}"],"alternate_names":["KAT6B-Related Disorders","Mental retardation unusual facies hypothyroidism","OHDO SYNDROME, SBBYS VARIANT","SAY-BARBER-BIESECKER-YOUNG-SIMPSON SYNDROME","Say-Barber-Biesecker Variant of Ohdo Syndrome","Say-Barber-Biesecker-Young-Simpson variant of Ohdo Syndrome","Young Simpson syndrome"],"keywords":[],"medgen_id":"C1863557","name":"Blepharophimosis - intellectual disability syndrome, SBBYS type"}
{"type":"Disease","attribute_content":[],"id":"585","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"24260777\",\"@Source\":\"PubMed\"},{\"$\":\"NBK169615\",\"@Source\":\"BookShelf\"}]}}","public_definition":"Biotin-thiamine-responsive basal ganglia disease (BTBGD) may present in childhood, early infancy, or adulthood. The classic presentation of BTBGD occurs in childhood (age 3-10 years) and is characterized by recurrent subacute encephalopathy manifest as confusion, seizures, ataxia, dystonia, supranuclear facial palsy, external ophthalmoplegia, and/or dysphagia which, if left untreated, can eventually lead to coma and even death. Dystonia and cogwheel rigidity are nearly always present; hyperreflexia, ankle clonus, and Babinski responses are common. Hemiparesis or quadriparesis may be seen. Episodes are often triggered by febrile illness or mild trauma or stress. Simple partial or generalized seizures are easily controlled with antiepileptic drugs. An early-infantile Leigh-like syndrome / atypical infantile spasms presentation occurs in the first three months of life with poor feeding, vomiting, acute encephalopathy, and severe lactic acidosis. An adult-onset Wernicke-like encephalopathy presentation is characterized by acute onset of status epilepticus, ataxia, nystagmus, diplopia, and ophthalmoplegia in the second decade of life. Prompt administration of biotin and thiamine early in the disease course results in partial or complete improvement within days in the childhood and adult presentations, but most with the infantile presentation have had poor outcome even after supplementation with biotin and thiamine.","alternate_symbols":["BBGD","BTBGD"],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0011841\"}","{\"db\":\"OMIM\",\"id\":\"607483\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"199348\"}","{\"db\":\"Orphanet\",\"id\":\"65284\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Basal+Ganglia+Disease%2C+Biotin-Responsive/756\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Biotin-thiamine-responsive basal ganglia disease\"}","{\"db\":\"OMIM\",\"id\":\"607483\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ENCEPHALOPATHY, THIAMINE-RESPONSIVE\"}","{\"db\":\"OMIM\",\"id\":\"606152.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"THIAMINE METABOLISM DYSFUNCTION SYNDROME 2 (BIOTIN- OR THIAMINE-RESPONSIVE TYPE)\"}","{\"db\":\"OMIM\",\"id\":\"606152.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"THIAMINE METABOLISM DYSFUNCTION SYNDROME 2 (BIOTIN- OR THIAMINE-RESPONSIVE TYPE)\"}","{\"db\":\"OMIM\",\"id\":\"606152.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"THIAMINE METABOLISM DYSFUNCTION SYNDROME 2 (BIOTIN- OR THIAMINE-RESPONSIVE TYPE)\"}","{\"db\":\"OMIM\",\"id\":\"606152.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"THIAMINE METABOLISM DYSFUNCTION SYNDROME 2 (BIOTIN- OR THIAMINE-RESPONSIVE TYPE)\"}","{\"db\":\"OMIM\",\"id\":\"606152.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"THIAMINE METABOLISM DYSFUNCTION SYNDROME 2 (BIOTIN- OR THIAMINE-RESPONSIVE TYPE)\"}","{\"db\":\"OMIM\",\"id\":\"606152.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"THIAMINE METABOLISM DYSFUNCTION SYNDROME 2 (BIOTIN- OR THIAMINE-RESPONSIVE TYPE)\"}","{\"db\":\"OMIM\",\"id\":\"606152.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"THIAMINE METABOLISM DYSFUNCTION SYNDROME 2 (BIOTIN- OR THIAMINE-RESPONSIVE TYPE)\"}","{\"db\":\"OMIM\",\"id\":\"607483\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"THIAMINE METABOLISM DYSFUNCTION SYNDROME 2 (BIOTIN- OR THIAMINE-RESPONSIVE TYPE)\"}","{\"db\":\"OMIM\",\"id\":\"607483\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"BBGD\"}","{\"db\":\"OMIM\",\"id\":\"607483\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"BTBGD\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0011841\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK169615\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"607483\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":["Biotin-thiamine-responsive basal ganglia disease","ENCEPHALOPATHY, THIAMINE-RESPONSIVE","THIAMINE METABOLISM DYSFUNCTION SYNDROME 2 (BIOTIN- OR THIAMINE-RESPONSIVE TYPE)","Thiamine Metabolism Dysfunction Syndrome 2","Thiamine metabolism dysfunction syndrome 2 (biotin- or thiamine-responsive encephalopathy type 2)"],"keywords":[],"medgen_id":"C1843807","symbol":"THMD2","name":"Biotin-responsive basal ganglia disease"}
{"type":"Disease","attribute_content":[],"id":"15784","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"32790266\",\"@Source\":\"PubMed\"},{\"$\":\"NBK560442\",\"@Source\":\"BookShelf\"}]}}","public_definition":"THOC6 intellectual disability syndrome is associated with moderate-to-severe developmental delay or intellectual disability; nonspecific dysmorphic facial features (tall forehead, deep-set eyes, short and upslanted palpebral fissures, epicanthal folds, and long nose with low-hanging columella); microcephaly (typically 2-3 SD below the mean); teeth anomalies (dental caries, malocclusion, and supernumerary teeth); cardiac anomalies (most typically atrial and/or ventricular septal defects); prenatal ventriculomegaly and hydrocephalus; cryptorchidism in males; and renal malformations (most commonly unilateral renal agenesis). More rarely, affected individuals may have hypergonadotropic hypogonadism (in females), seizures, poor growth, feeding difficulties, hearing loss, refractive errors and/or other eye abnormalities, vertebral anomalies, micro/retrognathia, and imperforate / anteriorly placed anus.","alternate_symbols":["MMRFCGU"],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0013362\"}","{\"db\":\"OMIM\",\"id\":\"613680\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"363444\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK560442\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"613680\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":["Microcephaly, mental retardation, and distinctive facies, with cardiac and genitourinary malformations"],"keywords":[],"medgen_id":"C3150939","symbol":"BBIS","name":"Beaulieu-Boycott-Innes syndrome"}
{"type":"Disease","attribute_content":[],"id":"2843","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"32790267\",\"@Source\":\"PubMed\"},{\"$\":\"NBK560443\",\"@Source\":\"BookShelf\"}]}}","public_definition":"Individuals with MN1 C-terminal truncation (MCTT) syndrome have mild-to-moderate intellectual disability, severe expressive language delay, dysmorphic facial features (midface hypoplasia, downslanting palpebral fissures, hypertelorism, exophthalmia, short upturned nose, and small low-set ears), and distinctive findings on brain imaging (including perisylvian polymicrogyria and atypical rhombencephalosynapsis). Mild-to-moderate prelingual hearing loss (usually bilateral, conductive, and/or sensorineural) is common. Generalized seizures (observed in the minority of individuals) are responsive to antiepileptic drugs. There is an increased risk for craniosynostosis and, thus, increased intracranial pressure. To date, 25 individuals with MCTT syndrome have been identified.","alternate_symbols":[],"xrefs":["{\"db\":\"OMIM\",\"id\":\"607174\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"263662\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Meningioma%2C+familial/8813\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK560443\",\"ref_field\":\"public_definition\"}"],"alternate_names":["Meningioma, familial, susceptibility to"],"keywords":["Neoplasm"],"medgen_id":"C3551915","name":"Meningioma, familial"}
{"type":"Disease","attribute_content":[],"id":"5568","content":"{\"Citation\":[{\"@Abbrev\":\"Int'l SCC for CMD, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"21078917\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301468\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1291\",\"@Source\":\"BookShelf\"}]}]}","alternate_symbols":["MDC1C"],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0011688\"}","{\"db\":\"OMIM\",\"id\":\"606612\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"52428\"}","{\"db\":\"OMIM\",\"id\":\"606612\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY, CONGENITAL, 1C\"}","{\"db\":\"OMIM\",\"id\":\"606612\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY, CONGENITAL, FKRP-RELATED\"}","{\"db\":\"OMIM\",\"id\":\"606612\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH OR WITHOUT IMPAIRED INTELLECTUAL DEVELOPMENT), TYPE B, 5\"}","{\"db\":\"OMIM\",\"id\":\"606612\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"MDC1C\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Congenital+muscular+dystrophy-dystroglycanopathy+%28with+or+with\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"606612\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":["MUSCULAR DYSTROPHY, CONGENITAL, 1C","MUSCULAR DYSTROPHY, CONGENITAL, FKRP-RELATED","MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH OR WITHOUT IMPAIRED INTELLECTUAL DEVELOPMENT), TYPE B, 5"],"keywords":[],"medgen_id":"C1847759","symbol":"MDDGB5","name":"Congenital muscular dystrophy-dystroglycanopathy (with or without mental retardation) type B5"}
{"type":"Disease","attribute_content":[],"id":"2985","content":"{\"Citation\":[{\"@Abbrev\":\"Int'l SCC for CMD, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"21078917\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301468\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1291\",\"@Source\":\"BookShelf\"}]}]}","alternate_symbols":["MDC1D"],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0012138\"}","{\"db\":\"OMIM\",\"id\":\"608840\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"98894\"}","{\"db\":\"OMIM\",\"id\":\"608840\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY, CONGENITAL, LARGE-RELATED\"}","{\"db\":\"OMIM\",\"id\":\"608840\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY, CONGENITAL, TYPE 1D\"}","{\"db\":\"OMIM\",\"id\":\"603590.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH IMPAIRED INTELLECTUAL DEVELOPMENT), TYPE B, 6\"}","{\"db\":\"OMIM\",\"id\":\"603590.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH IMPAIRED INTELLECTUAL DEVELOPMENT), TYPE B, 6\"}","{\"db\":\"OMIM\",\"id\":\"603590.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH IMPAIRED INTELLECTUAL DEVELOPMENT), TYPE B, 6\"}","{\"db\":\"OMIM\",\"id\":\"603590.0008\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH IMPAIRED INTELLECTUAL DEVELOPMENT), TYPE B, 6\"}","{\"db\":\"OMIM\",\"id\":\"608840\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH IMPAIRED INTELLECTUAL DEVELOPMENT), TYPE B, 6\"}","{\"db\":\"OMIM\",\"id\":\"608840\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"MDC1D\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Congenital+muscular+dystrophy-dystroglycanopathy+with+mental+retardation%2C+type+B6/8075\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"608840\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_names":["MUSCULAR DYSTROPHY, CONGENITAL, LARGE-RELATED","MUSCULAR DYSTROPHY, CONGENITAL, TYPE 1D","MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH IMPAIRED INTELLECTUAL DEVELOPMENT), TYPE B, 6"],"keywords":[],"medgen_id":"C1837229","symbol":"MDDGB6","name":"Congenital muscular dystrophy-dystroglycanopathy with mental retardation, type B6"}
{"type":"Disease","attribute_content":[],"id":"16780","gard_id":"6051","disease_mechanism":"loss of function","alternate_symbols":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0005516\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000238852\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000321063\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000525804\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000591289\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6051\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Osteochondrodysplasia/9053\",\"ref_field\":\"name\"}"],"alternate_names":[],"keywords":[],"medgen_id":"C0029422","symbol":"DTDST-related dysplasias","disease_mechanism_id":"273","name":"Osteochondrodysplasia"}
{"type":"Disease","attribute_content":[],"id":"10967","gard_id":"9152","disease_mechanism":"loss of function","alternate_symbols":["HSD3B2","HSDB"],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0008727\"}","{\"db\":\"MeSH\",\"id\":\"C579862\"}","{\"db\":\"OMIM\",\"id\":\"201810\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"90791\"}","{\"db\":\"OMIM\",\"id\":\"201810\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 3-BETA-HYDROXYSTEROID DEHYDROGENASE 2 DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"613890.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 3-BETA-HYDROXYSTEROID DEHYDROGENASE 2 DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"613890.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 3-BETA-HYDROXYSTEROID DEHYDROGENASE 2 DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"613890.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 3-BETA-HYDROXYSTEROID DEHYDROGENASE 2 DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"613890.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 3-BETA-HYDROXYSTEROID DEHYDROGENASE 2 DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"613890.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 3-BETA-HYDROXYSTEROID DEHYDROGENASE 2 DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"613890.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 3-BETA-HYDROXYSTEROID DEHYDROGENASE 2 DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"613890.0008\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 3-BETA-HYDROXYSTEROID DEHYDROGENASE 2 DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"613890.0009\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 3-BETA-HYDROXYSTEROID DEHYDROGENASE 2 DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"613890.0010\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 3-BETA-HYDROXYSTEROID DEHYDROGENASE 2 DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"613890.0011\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 3-BETA-HYDROXYSTEROID DEHYDROGENASE 2 DEFICIENCY\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000320609\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"HSD3B2\"}","{\"db\":\"OMIM\",\"id\":\"201810\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"HSDB\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000320609\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000503060\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508723\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000555663\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000591289\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9152\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"3-Beta-Hydroxysteroid+Dehydrogenase+Deficiency/30\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"54470008\",\"ref_field\":\"name\"}"],"alternate_names":["3-beta-HSD deficiency","3b-hydroxysteroid dehydrogenase deficiency","ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 3-BETA-HYDROXYSTEROID DEHYDROGENASE 2 DEFICIENCY","Adrenal hyperplasia 2","Adrenal hyperplasia II","HSD3B deficiency","Type II 3-beta-hydroxysteroid dehydrogenase deficiency"],"keywords":[],"medgen_id":"C0342471","disease_mechanism_id":"273","name":"3 beta-Hydroxysteroid dehydrogenase deficiency"}
{"type":"Disease","attribute_content":["{\"Attribute\":{\"$\":\"loss of function\",\"@Type\":\"disease mechanism\",\"@integerValue\":\"273\"},\"XRef\":[{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000246735\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000260631\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000520063\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000514924\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000520414\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528516\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000551442\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000520447\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528528\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000552214\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000556520\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000558532\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000505068\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000507480\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000507942\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000522527\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000568367\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000591289\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000325415\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000512526\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528276\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528500\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528536\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000556501\"}]}"],"id":"1790","content":"{\"Citation\":[{\"@Type\":\"general\",\"ID\":{\"$\":\"3009617\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301469\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1292\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"HFSA, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"20610207\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"NSGC, 2002\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"12735292\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"Eng et al., 2006\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"16980809\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"Salviati et al, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"2869001\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"EuroGentest, 2011\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"21934708\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2013\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"23788249\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"AHA/ASA, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25355838\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"NSGC, 2013\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"23860966\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ESC, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25173338\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2015\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"25356965\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2016\",\"@Type\":\"Recommendation\",\"ID\":[{\"$\":\"27854360\",\"@Source\":\"PubMed\"},{\"$\":\"10.1038/gim.2016.190\",\"@Source\":\"DOI\"}]}]}","public_definition":"Fabry disease results from deficient activity of the enzyme alpha-galactosidase A (a-Gal A) and progressive lysosomal deposition of globotriaosylceramide (GL-3) in cells throughout the body. The classic form, occurring in males with less than 1% a-Gal A enzyme activity, usually has its onset in childhood or adolescence with periodic crises of severe pain in the extremities (acroparesthesia), the appearance of vascular cutaneous lesions (angiokeratomas), sweating abnormalities (anhidrosis, hypohidrosis, and rarely hyperhidrosis), characteristic corneal and lenticular opacities, and proteinuria. Gradual deterioration of renal function to end-stage renal disease (ESRD) usually occurs in men in the third to fifth decade. In middle age, most males successfully treated for ESRD develop cardiac and/or cerebrovascular disease, a major cause of morbidity and mortality. Heterozygous females typically have milder symptoms at a later age of onset than males. Rarely, they may be relatively asymptomatic throughout a normal life span or may have symptoms as severe as those observed in males with the classic phenotype. In contrast, males with greater than 1% a-Gal A activity may have: (1) a cardiac variant phenotype that usually presents in the sixth to eighth decade with left ventricular hypertrophy, cardiomyopathy and arrhythmia, and proteinuria, but without ESRD; or (2) a renal variant phenotype, associated with ESRD but without the skin lesions or pain; or (3) cerebrovascular disease presenting as stroke or transient ischemic attack.","gard_id":"6400","disease_mechanism":"Fabry disease is due to inactivating mutations in the X-linked GLA gene resulting in deficiency of the enzyme Alpha Galactosidase-A.","alternate_symbols":[],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001071\",\"type\":\"primary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0010526\"}","{\"db\":\"OMIM\",\"id\":\"301500\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"324\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001071\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Angiokeratoma corporis diffusum\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001071\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Fabry syndrome\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Fabry+Disease/2690\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Fabry's disease\"}","{\"db\":\"SNOMED CT\",\"id\":\"16652001\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Fabry's disease\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000500007\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6400\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"fabry-disease\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1292\",\"ref_field\":\"public_definition\"}"],"alternate_names":["Alpha-galactosidase A deficiency","Anderson-Fabry disease","Angiokeratoma corporis diffusum","Angiokeratoma, diffuse","Ceramide trihexosidase deficiency","Ceramide trihexosidosis","Fabry syndrome","Fabry's disease","GLA deficiency","Hereditary dystopic lipidosis"],"keywords":[],"medgen_id":"C0002986","name":"Fabry disease"}
